NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRIW)

0.1750

+0.0050

+(2.94%)

At close: May 16 at 4:00:00 PM EDT

Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Biofrontera Inc (BFRI) reports a 9% revenue increase and key clinical milestones, while addressing cash flow and restructuring challenges.

GuruFocus.com 3 days ago

BFRIW
+2.94%
Q1 2025 Biofrontera Inc Earnings Call

Q1 2025 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents 3 days ago

BFRIW
+2.94%
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025

GlobeNewswire 4 days ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side effects associated with some systemic therapies4Approximately 50 million people in the US are suffering from acne vulgaris, including both adolescents and adults1,2The US acne treatment market was valued at $5.7 billion in 2024 and is growing annually5 WOBURN, Ma

GlobeNewswire 5 days ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

WOBURN, MA / ACCESS Newswire / May 6, 2025 /Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for ...

ACCESS Newswire 14 days ago

BFRI

BFRIW
+2.94%
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and EuromelanomaThe Hats On Challenge provides an opportunity to take part in raising awareness of AK.Actinic Keratosis (AK) is a rough, scaly patch on the skin caused by years of sun exposure. If left untreated, AK can develop into squamous cell carcinoma, a type of skin cancer. Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI

GlobeNewswire 19 days ago

BFRI

BFRIW
+2.94%
Biofrontera Full Year 2024 Earnings: Misses Expectations

Biofrontera ( NASDAQ:BFRI ) Full Year 2024 Results Key Financial Results Revenue: US$37.3m (up 9.5% from FY 2023). Net...

Simply Wall St. last month

BFRI

BFRIW
+2.94%
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

Biofrontera Inc (BFRI) reports significant revenue growth and strategic advancements, yet faces ongoing net losses and financial hurdles.

GuruFocus.com last month

BFRIW
+2.94%
Q4 2024 Biofrontera Inc Earnings Call

Q4 2024 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents last month

BFRIW
+2.94%
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $3

GlobeNewswire last month

BFRI

BFRIW
+2.94%
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today a

GlobeNewswire 2 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Ca

GlobeNewswire 2 months ago

BFRI

BFRIW
+2.94%
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?

Biofrontera Inc. ( NASDAQ:BFRI ) is possibly approaching a major achievement in its business, so we would like to shine...

Simply Wall St. 2 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024.BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera”

GlobeNewswire 4 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.Biofrontera’s RhodoLED XL and BF-RhodoLED lamps deliver red light energy using long-lasting light-emitting diode (LED) arrays. WOBURN, Mass., Dec

GlobeNewswire 4 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced it will ...

ACCESS Newswire 5 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the completion of a private placement of a $4.2 million senior secured convertible note (the “Note”) with its principal shareholders. The Note matures on November 22, 2027, bears a paid in kind interest of 10% per annum and is secured by the Company’s asse

GlobeNewswire 5 months ago

BFRI

BFRIW
+2.94%
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc (BFRI) reports significant clinical progress and cost reductions, despite weather-related shipment delays impacting Q3 revenue.

GuruFocus.com 6 months ago

BFRIW
+2.94%
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

BFRIW
+2.94%
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not delayed due to Hurricane Milton. ●Total revenues for the first 9 months were $24.8 million, an increase of $1.3 million, or 5.6% as compared to the same period last year. Without the impact of Hurricane Milton delaying shipments, the increase would have been 12%. ●Ameluz® achieved record volume in September 2024. ●Organization continues to pru

GlobeNewswire 6 months ago

BFRI

BFRIW
+2.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biofrontera Inc. (BFRIW)

Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Q1 2025 Biofrontera Inc Earnings Call

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Biofrontera Full Year 2024 Earnings: Misses Expectations

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

Q4 2024 Biofrontera Inc Earnings Call

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit?

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update